Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Energy and Commerce advances several health bills including cell‑and‑tissue safety, lung‑cancer research, and seniors’ medication access
Loading...
Summary
The committee considered a package of health bills alongside the SUPPORT Act. Lawmakers advanced measures on tissue safety, lung cancer research, and a change to Medicare Part D dispensing rules for some specialty drugs. Debate on several bills reflected broader concerns about NIH and HHS staffing and proposed Medicaid cuts.
Beyond the SUPPORT Act reauthorization and the Charlotte Woodward bill, the committee considered and advanced several additional health measures during the markup:
- Human Cell and Tissue Product Safety (Chandra Isanga) — HR 10 82: Sponsors said the bill responds to a cluster of infections linked to contaminated tissue grafts and would require HHS action to improve oversight, education and civil penalties for unsafe suppliers. Representative Debbie Dingell (D-Mich.) described the bill as a response to patient deaths linked to contaminated bone graft material and urged passage. The committee passed the bill following discussion.
- Women in Lung Cancer Research and Preventive Services — HR 23 19: The bill would direct an interagency review of research on lung cancer among women and underserved populations and expand early detection and prevention work. Representatives warned that broader HHS and NIH staffing and alleged grant cancelations could limit the research this bill seeks to support. The committee took up and adopted the underlying bill after debate; several Members used the debate to press for protections for NIH-funded research.
- Seniors Access to Critical Medications Act — HR 24 84: This bill would allow Medicare Part D beneficiaries, under certain circumstances, to receive prescriptions by mail or through authorized caregivers picking up medications. Sponsors said the change is aimed at improving access for homebound seniors and patients with complex needs; opponents raised concerns that broad authorization could create incentives for vertical consolidation by large integrated health companies and urged safeguards. The committee approved the bill and sponsored votes were recorded.
Why it matters: Each measure tackles discrete health‑system problems — infection control in human tissue products, inequities in lung‑cancer research and practical barriers for seniors getting specialty medications — but debate about each bill repeatedly returned to larger concerns: changes at HHS (staffing and organizational shifts), the legal and budgetary status of NIH grants, and the possibility of Medicaid reductions in forthcoming budget reconciliation work.
What to watch: Sponsors of the lung‑cancer research bill and other Members said they will push for safeguards to ensure the agency capacity and grant funding exist to carry out the legislation’s aims. Supporters of the Medicare prescription flexibilities said additional guardrails addressing financial conflicts and dispensing safeguards could be considered as the bills move to the House floor.
